NGM313

NGM Biopharmaceuticals, Inc · Phase 1 active Biologic

At a glance

Generic name	NGM313
Sponsor	NGM Biopharmaceuticals, Inc
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (PHASE2)
Study of NGM313 in Obese Participants (PHASE1)
Phase 1 Study of NGM313 in Healthy Adult Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NGM313 CI brief — competitive landscape report
NGM313 updates RSS · CI watch RSS
NGM Biopharmaceuticals, Inc portfolio CI